PMCB
PharmaCyte Biotech Inc.
$1.00
+$0.02(+2.03%)
52
Overall
80
Value
25
Tech
--
Quality
Market Cap
$6.66M
Volume
77.81K
52W Range
$0.80 - $2.42
Target Price
$NaN
Order:
Income Statement
| Metric | Trend | Chart | 2016 Apr | 2017 Apr | 2018 Apr | 2019 Apr | 2020 Apr | 2021 Apr | 2022 Apr | 2023 Apr | 2024 Apr | 2025 Apr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-6.1M | $-4.4M | $-7.0M | $-4.1M | $3.8M | $3.6M | $4.4M | $6.5M | $8.5M | $4.4M | ||
| Research & Development | $1.4M | $1.2M | $2.0M | $460.1K | $301.2K | $916.2K | $690.9K | $468.5K | $407.4K | $438.4K | ||
| Research Expense | $1.4M | $1.2M | $2.0M | $460.1K | $301.2K | $916.2K | $690.9K | $468.5K | $407.4K | $438.4K | ||
| Selling, General & Administrative | $2.7M | $1.2M | $2.8M | $1.7M | $1.9M | $1.3M | $2.2M | $4.8M | $6.1M | $3.9M | ||
| Selling & Marketing Expenses | -- | $65.5K | $326.5K | -- | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $2.7M | $1.2M | $2.4M | $1.7M | $1.9M | $1.3M | $2.2M | $4.8M | $6.1M | $3.9M | ||
| Salaries & Wages | $1.9M | $2.0M | $2.2M | $1.6M | $1.6M | $1.4M | $1.5M | $1.2M | $1.3M | -- | ||
| Depreciation & Amortization | -- | -- | -- | $406.8K | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | -- | -- | -- | $406.8K | -- | -- | -- | -- | -- | -- | ||
| Amortization | -- | -- | -- | $406.8K | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | $-6.1M | $-4.4M | -- | -- | $31.0K | $20.4K | $19.3K | $23.4K | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-6.0M | $-4.4M | $-7.0M | $-4.1M | $-3.8M | $-3.6M | $-4.4M | $-6.5M | $-8.5M | $-4.4M | ||
| EBITDA | $-6.0M | $-4.4M | $-6.8M | $-4.1M | $-3.8M | $-3.5M | $-4.2M | $-5.2M | $333.8K | $30.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $1.2K | $1.5K | -- | -- | $453 | $3.0K | $509 | -- | -- | -- | ||
| Intinc | -- | -- | -- | -- | -- | -- | $157.6K | $1.9M | $3.4M | $1.4M | ||
| Net Non-Operating Interest Income/Expense | $-1.2K | $-1.5K | -- | -- | $-453 | $-3.0K | $157.1K | $1.9M | $3.4M | $1.4M | ||
| Other Income/Expense | $-10.5K | $1.5K | $-152.6K | $-33.4K | $40 | $-74.8K | $-4.3K | $-202.0K | $3.4M | $2.0M | ||
| Other Special Charges | $10.5K | $-1.5K | $152.6K | $33.4K | $-40 | $74.8K | $-4.3K | $202.0K | $191.1K | $-965 | ||
| SPECIAL ITEMS | ||||||||||||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | $2.0M | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-6.0M | $-4.4M | $-6.8M | $-4.1M | $-3.8M | $-3.5M | $-4.2M | $-5.2M | $333.8K | $30.7M | ||
| Pre-Tax Income | $-6.1M | $-4.4M | $-6.8M | $-4.1M | $-3.8M | $-3.6M | $-4.2M | $-4.3M | $-6.5M | $-4.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-195.2K | -- | $-887.7K | $-6.5K | $-803.6K | $-745.8K | $-890.2K | $-906.4K | -- | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-6.1M | $-4.4M | $-6.8M | $-4.1M | $-3.8M | $-3.6M | $-4.2M | $-4.3M | $333.8K | $30.7M | ||
| Net Income (Continuing Operations) | $-6.1M | $-4.4M | $-6.8M | $-4.1M | $-3.8M | $-3.6M | $-4.2M | $-4.3M | $333.8K | $30.7M | ||
| Net Income (Discontinued Operations) | $-6.1M | $-4.4M | $-6.8M | $-4.1M | $-3.8M | $-3.6M | $-4.2M | $-4.3M | $333.8K | $30.7M | ||
| Net Income (Common Stockholders) | $-6.1M | $-4.4M | $-6.8M | $-4.1M | $-3.8M | $-3.6M | $-4.2M | $-4.3M | $-17.2M | $23.4M | ||
| Normalized Income | -- | -- | -- | -- | -- | $-4.3M | $-5.1M | -- | -- | $-2.8M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-6.1M | $4.4M | $-7.0M | $-4.1M | $3.8M | $3.6M | $4.4M | $6.5M | $8.5M | $4.4M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $501.6K | $563.5K | $645.8K | $733.4K | $903.8K | $1.4M | $15.5M | $19.5M | $9.6M | $7.3M | ||
| Average Shares Outstanding (Diluted) | $501.6K | $563.5K | $645.8K | $733.4K | $903.8K | $1.4M | $15.5M | $19.5M | $9.6M | $7.3M | ||
| Shares Outstanding | $565.4K | $648.8K | $694.0K | $885.4K | $1.6M | $1.6M | $20.7M | $8.8M | $7.7M | $6.8M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-2.45 | $-0.27 | $-0.22 | $-1.8 | $3.19 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-2.45 | $-0.27 | $-0.22 | $-1.8 | $3.19 | ||
| Diluted EPS | $-15 | $-15 | $-15 | -- | -- | $-2.45 | $-0.27 | $-0.22 | $-1.8 | $3.19 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-0.27 | $-0.22 | $-1.8 | $3.19 | ||
| OTHER METRICS | ||||||||||||
| Accretion On Preferred Stock | -- | -- | -- | -- | -- | -- | -- | -- | $15.1M | $3.2M | ||
| Accrued Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | -- | -- | $2.5M | $1.1M | ||
| Acquisition Expense | -- | -- | -- | $406.8K | -- | -- | -- | -- | -- | -- | ||
| Development Expense | -- | $65.5K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | -- | -- | -- | -- | $5.9K | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | -- | -- | -- | $5.9K | -- | -- | ||
| Fees | $-45.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | -- | -- | $-1.6M | $-2.0M | ||
| Interest Expense Operating | $45.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Marketing Expense | -- | $65.5K | $326.5K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $2.7M | $1.2M | $2.4M | $1.7M | $1.9M | $1.3M | $2.2M | $4.8M | $6.1M | $3.9M | ||
| Other Write Down | -- | -- | $326.5K | -- | -- | -- | -- | -- | -- | -- | ||
| Otherunder Preferred Stock Dividend | -- | -- | -- | -- | -- | -- | -- | -- | $17.6M | $4.3M | ||
| Preferred Stock Dividends | -- | -- | -- | -- | -- | -- | -- | -- | $17.6M | $4.3M | ||
| Rent And Landing Fees | $2.3M | $744.8K | $1.8M | $1.4M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PMCB | $1.00 | +2.0% | 77.81K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |